• The use of beta-glucan as an immunomodulatory therapy in frequently and chronically ill patients
en To content

The use of beta-glucan as an immunomodulatory therapy in frequently and chronically ill patients

SOVREMENNAYA PEDIATRIYA. 2014. 5(61):106-110doi 10.15574/SP.2014.61.106 

The use of beta-glucan as an immunomodulatory therapy in frequently and chronically ill patients

Himich Т. Y. 
Kharkov National Medical University, Ukraine

The beta-glucans are the multiple-vector modulators of the organism biological reactivity with a significant immunomodulatory potential. The researching results recommend their using as a prevention and treatment of the recurrent bacterial, viral, fungal, parasitic infections in terms of primary and secondary immunodeficiency of various etiologies and in allergic diseases.

Key words: immunodeficiency, immunomodulatory, beta-glucan.

1. Беседнова НН, Иванушко ЛА, Звягинцева ТН и др. 2000. Иммунотропные свойства 1,3/1,6-β-D-глюканов. Антибиотики и химиотерапия 2: 37—44.

2. Хаитов PM, Пинегин БВ, Истамов ХИ. 1995. Экологическая иммунология. М: 92—93.

3. Thornton BP, Vetvicka V, Pitman M et al. 1996. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 156(3): 1235—1246.

4. Bohn JA, BeMille JN. 1995. (1->3)-β-d-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydrate Polymers 28(1): 3—14.

5. Brown GD, Gordon S. 2001. Immune recognition. A new receptor for beta-glucans. Nature 413(6851): 36—37.

6. Brown GD, Taylor PR, Reid DM et al. 2002. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 196(3): 407—412.

7. Doll M, Hauss R, Spermezan R. 2005. Anwendungsbeobachtung: Immunmodulierende Wirkung von (1,3),(1,6)-β-D-Glucan-Gezeigt an der Neopterin- und b-Defensin-Synthese. Naturheilpraxis 5: 676—681.

8. De Felippe Junior J, da Rocha e Silva Junior M, Maciel FM et al. 1993. Infection prevention in patients with severe multiple trauma with the immu"

nomodulator beta 1—3 polyglucose (glucan). Surg Gynecol Obstet 177(4): 383—388.

9. Jesenak M, Hrubisko M et al. 2010. Czech-Slov Pediat 65(11): 639—647.

10. Jesenak M, Majtan J et al. 2013. Int immunopharmacol 15(2): 395—399. http://dx.doi.org/10.1016/j.intimp.2012.11.020

11. Young SH, Ye J, Frazer DG et al. 2001. Molecular mechanism of tumor necrosis factor-alpha production in 1->3-beta-glucan (zymosan)-activated macrophages. J Biol Chem 276(23): 20781—20787.

12. Lehne G, Haneberg B, Gaustad P et al. 2006. Oral administration of a new soluble branched beta-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. Clin Exp Immunol 143(1): 65—69.

13. Sugiyama A, Hata S, Suzuki K et al. 2010. Oral administration of paramylon, a beta-1,3-D-glucan isolated from Euglena gracilis Z inhibits development of atopic dermatitis-like skin lesions in NC/Nga mice. J Vet Med Sci 72(6): 755—763. http://dx.doi.org/10.1292/jvms.09-0526

14. Babineau TJ, Marcello P, Swails W et al. 1994. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 220(5): 601—609.

15. Sandula J, Machova E, Hribalova V. 1995. Mitogenic activity of particulate yeast beta-(1->3)-D-glucan and its water-soluble derivatives. Int J Biol Macromol 17(6): 323—326.

16. Sapena Grau, Pico Sirvent et al. 2012. Poster presented at XVIII National Pharmaceutical Congress in Santader, Spain.

17. Seijelid R, Bogwald J, Lundwall A. 1981. Glycan stimulation of macrophages in vitro. Exp Cell Res 131(1): 121—129.

18. Okazaki M, Adachi Y, Ohno N, Yadomae T. 1995. Structure-activity relationship of (1->3)-beta-D-glucans in the induction of cytokine production from macrophages, in vitro. Biol Pharm Bull 18(10): 1320—1327.

19. Woo YI, Park BJ, Kim HL et al. 2010. The biological activities of (1,3)-(1,6)-beta-d-glucan and porous electrospun PLGA membranes containing beta-glucan in human dermal fibroblasts and adipose tissue-derived stem cells. Biomed Mater 5(4): P. 044109. http://dx.doi.org/10.1088/1748-6041/5/4/044109

20. Meira DA, Pereira PC, Marcondes-Machado J et al. 1996. The use of glucan as immunostimulant in the treatment of paracoccidioidomycosis. Am J Trop Med Hyg 55(5): 496—503.

21. Williams DL. 1997. Overview of (1->3)-beta-D-glucan immunobiology. Mediators Inflamm 6(4): 247—250.